Nenocorilant features among the latest industry projects newly into phase 1.
ApexOnco Front Page
Recent articles
A deal with Jacobio is worth $100m up front.
Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.
Herthena-Lung02 data are an ASCO shocker.
Petosemtamab and ficerafusp alfa are among the biologicals to be featured at ASCO.
Roche’s PI3Kα inhibitor continues to pull away from Novartis’s Piqray.
A pivotal trial of the group’s mutant-selective PI3Kα inhibitor, RLY-2608, will start in July.
The company's refusal to run a randomised pivotal study of UGN-102 leads to an adcom thumbs down.
